Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesEarnAISquareMore
Palantir's AIPCon Highlights Data Sovereignty Demand, Ecosystem Adoption, Oppenheimer Says

Palantir's AIPCon Highlights Data Sovereignty Demand, Ecosystem Adoption, Oppenheimer Says

MT newswireMT newswire2026/09/14 15:56
11:56 AM EDT, 09/14/2026 (MT Newswires) -- Palantir Technologies' (PLTR) AIPCon 11 highlighted growing demand for data sovereignty, with customers and partners increasingly building products and infrastructure on Palantir's platform, Oppenheimer said in a Monday note. The analyst highlighted Nvidia's (NVDA) use of Palantir's Ontology with its optimization and AI models in an on-premise deployment, with the companies planning to extend the reference architecture to manufacturing, energy, healthcare, automotive and aerospace customers. Oppenheimer pointed to recent partnerships with Nebius (NBIS), Fujitsu, Method Security and PwC, along with customer deployments at Acrisure, Novartis (NVS) and Ondas (ONDS), as evidence of expanding ecosystem adoption that could deepen switching costs as customers build and monetize products on Palantir's Ontology. The brokerage also highlighted government expansion, including an FAA safety management system and L3Harris Technologies' (LHX) defense-wide data layer, saying sovereign AI demand, new infrastructure commitments and commercial and government deployments support continued growth momentum. Oppenheimer reiterated its outperform rating on the stock with a price target of $200. Palantir Technologies shares were up 2.6% in Monday trading. Price: 171.61, Change: +4.38, Percent Change: +2.62
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

After Eli Lilly's nearly 300% surge in four years, Wall Street remains bullish: The "hidden pipeline" beyond GLP-1 is underestimated

Eli Lilly’s share price has surged nearly 300% since the approval of its first GLP-1 drug, with its market capitalization surpassing 1 trillion USD, yet Wall Street remains optimistic about its continued growth. Berenberg has upgraded Eli Lilly’s rating to “Buy," believing that Mounjaro and Zepbound will continue to see strong volume, and that the oral GLP-1 drug could further drive demand. Additionally, Eli Lilly continues to expand into areas such as cancer and sleep disorders, and the potential of its non-obesity-related pipelines remains underestimated by the market.

华尔街见闻2026/09/18 13:21